Antibody-drug conjugates (ADCs) are a novel class of cancer therapeutics comprised of a linker-payload conjugated to a selective monoclonal antibody targeting a tumor-associated antigen (TAA) to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback